Stryker is my defensive-growth anchor: a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.
Catalysts: the Mako robotic-surgery platform expanding its installed base (and recurring revenue), steady procedure volumes, and disciplined bolt-on M&A. Recurring consumables make the model sticky.
My base case: revenue growth of ~9–11%/yr, gradual margin expansion, and a fair multiple of ~22–23x — giving a base-case Fair Value near $375 (bear ~$330, bull ~$415). At ~19–20x forward earnings, it's reasonably valued for its quality.
Risks: hospital capex cycles, pricing pressure, integration risk from acquisitions, and a premium valuation that leaves little room for execution slips. It's a compounder, not a bargain.
My plan is to hold as the more defensive sleeve of my portfolio, reinvest dividends, and add on weakness — a lower-volatility complement to my tech positions. (Personal thesis, not financial advice.)
Have other thoughts on Stryker?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
The user duarte_EM holds no position in NYSE:SYK. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
Aging Populations And Emerging Markets Will Transform Healthcare
View narrative
Investing in Stryker (SYK) should be an easy ride
View narrative
